Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopes

Matias Gutiérrez-González,Ahmed S. Fahad,Matt Ardito,Padma Nanaware,Liying Lu,Erica Normandin,Bharat Madan,Jacob Tivin,Emily Coates,Amy R. Henry,Farida Laboune,Barney S. Graham,Daniel C. Douek,Julie E. Ledgerwood,John R. Mascola,William D. Martin,Lawrence J. Stern,Annie S. De Groot,Brandon J. DeKosky
DOI: https://doi.org/10.1101/2021.01.15.426750
2021-01-01
Abstract:Human antibody responses are established by the generation of combinatorial sequence diversity in antibody variable domains, followed by iterative rounds of mutation and selection via T cell recognition of antigen peptides presented on MHC-II. Here, we report that MHC-II peptide epitope deletion from B cell receptors (BCRs) correlates with antibody development in vivo . Large-scale antibody sequence analysis and experimental validation of peptide binding revealed that MHC-II epitope removal from BCRs is linked to genetic signatures of T cell help, and donor-specific antibody repertoire modeling demonstrated that somatic hypermutation selectively targets the personalized MHC-II epitopes in antibody variable regions. Mining of class-switched sequences and serum proteomic data revealed that MHC-II epitope deletion is associated with antibody class switching and long-term secretion into serum. These data suggest that the MHC-II peptide epitope content of a BCR is an important determinant of antibody maturation that shapes the composition and durability of humoral immunity. Highlights ### Competing Interest Statement M.A., J.T., W.M., and A.S.G. are employees of Epivax, Inc., which commercializes the EpiMatrix prediction tool.
What problem does this paper attempt to address?